Giant cell arteritis : early diagnosis is key iyza

php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Eye and Brain 2019:11 1–12 Eye and Brain Dovepress

[1]  P. Chévez-Barrios,et al.  Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. , 2018, American journal of ophthalmology.

[2]  R. Boellaard,et al.  FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  I. Barshack,et al.  Negative temporal artery biopsy: predictive factors for giant cell arteritis diagnosis and alternate diagnoses of patients without arteritis , 2018, Clinical Rheumatology.

[4]  W. Schmidt.  Ultrasound in the diagnosis and management of giant cell arteritis , 2018, Rheumatology.

[5]  E. Matteson,et al.  Prevention of glucocorticoid morbidity in giant cell arteritis , 2018, Rheumatology.

[6]  A. Matucci,et al.  Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study , 2018, Angiology.

[7]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[8]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[9]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[10]  M. Tomšič,et al.  Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis , 2016, Medicine.

[11]  C. Salvarani,et al.  Biotherapies in large vessel vasculitis. , 2016, La Revue de medecine interne.

[12]  M. El-Dairi,et al.  Diagnostic Algorithm for Patients With Suspected Giant Cell Arteritis , 2015, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[13]  P. Merkel,et al.  Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study , 2015, The Journal of Rheumatology.

[14]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. , 2015, Seminars in arthritis and rheumatism.

[15]  M. Soussan,et al.  Management of Large-Vessel Vasculitis With FDG-PET , 2015, Medicine.

[16]  B. Dasgupta,et al.  Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. , 2015, Clinical and experimental rheumatology.

[17]  R. Watts.  2. Epidemiology of giant cell arteritis: a critical review , 2014 .

[18]  S. Flamm,et al.  Clinical Diagnosis and Management of Large Vessel Vasculitis: Giant Cell Arteritis , 2014, Current Cardiology Reports.

[19]  G. Kaplanski,et al.  Anti-TNF-Alpha Therapy and Systemic Vasculitis , 2014, Mediators of inflammation.

[20]  A. Perkins,et al.  Recognition and management of polymyalgia rheumatica and giant cell arteritis. , 2013, American family physician.

[21]  G. Baron,et al.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial , 2013, Annals of the rheumatic diseases.

[22]  J. Stone,et al.  Design of the Tocilizumab in Giant Cell Arteritis Trial , 2013, International journal of rheumatology.

[23]  V. Biousse,et al.  Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? , 2012, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[24]  M. Gershwin,et al.  Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. , 2012, Autoimmunity reviews.

[25]  P. Seo,et al.  Biologic agents in systemic vasculitis. , 2011, International journal of clinical rheumatology.

[26]  M. Walvick,et al.  Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. , 2011, Ophthalmology.

[27]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[28]  Javier Martín,et al.  Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.

[29]  A. Kawasaki,et al.  Giant cell arteritis: an updated review , 2009, Acta ophthalmologica.

[30]  T. Naka,et al.  Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. , 2008, Arthritis and rheumatism.

[31]  E. Mola,et al.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects , 2007, Annals of the rheumatic diseases.

[32]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[33]  R. Eberhardt,et al.  Giant Cell Arteritis: Diagnosis, Management, and Cardiovascular Implications , 2007, Cardiology in review.

[34]  G. Hunder,et al.  Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. , 2006, Arthritis and rheumatism.

[35]  M. González-Gay,et al.  Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. , 2006, Medicine.

[36]  W. Rahman,et al.  Giant cell (temporal) arteritis: an overview and update. , 2005, Survey of ophthalmology.

[37]  C. Nordborg,et al.  Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis , 2005, Annals of the rheumatic diseases.

[38]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[39]  S. Hayreh,et al.  Management of Giant Cell Arteritis , 2003, Ophthalmologica.

[40]  R. Sergott,et al.  Thrombocytosis in patients with biopsy-proven giant cell arteritis. , 2002, Ophthalmology.

[41]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[42]  R. Tomsak.  Giant cell arteritis. , 2002, Ophthalmology.

[43]  Colin C K Chan,et al.  Steroid management in giant cell arteritis , 2001, The British journal of ophthalmology.

[44]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[45]  G. Hunder,et al.  Giant cell arteritis with low erythrocyte sedimentation rate: Frequency of occurrence in a population‐based study , 2001 .

[46]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[47]  J. Evans,et al.  Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. , 2000, Arthritis and rheumatism.

[48]  S. Hayreh,et al.  Ocular manifestations of giant cell arteritis. , 1998, American journal of ophthalmology.

[49]  E. Gromnica-ihle,et al.  Color duplex ultrasonography in the diagnosis of temporal arteritis. , 1997, The New England journal of medicine.

[50]  S S Hayreh,et al.  Giant cell arteritis: validity and reliability of various diagnostic criteria. , 1997, American journal of ophthalmology.

[51]  L. A. Healey,et al.  Polymyalgia rheumatica and giant cell arteritis. , 1984, Western Journal of Medicine.

[52]  R. Walls.  Simple rule for calculating normal erythrocyte sedimentation rate. , 1983, British medical journal.

[53]  A. Miller,et al.  Simple rule for calculating normal erythrocyte sedimentation rate. , 1983, British medical journal.

[54]  I. Aranda-Valera,et al.  Diagnostic validity of Doppler ultrasound in giant cell arteritis. , 2017, Clinical and experimental rheumatology.

[55]  G. Haugeberg,et al.  The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? , 2016, Rheumatology.

[56]  Zhenjie Liu,et al.  [Pathogenesis of giant cell arteritis]. , 2012, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[57]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[58]  M. Bertoni,et al.  Diagnosis and Treatment of Giant Cell Arteritis , 2008, Drugs & aging.

[59]  J. Barrier.  Treatment of giant cell arteritis. , 1994, Annales de medecine interne.